2086-01-3

Basic information

• Product Name: N,N-dihydroxybenzenecarboximidamide
• CAS NO: 2086-01-3
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.153
• Mol File: 2086-01-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 343.9°Cat760mmHg
• Flash Point: 161.8°C
• Density: 1.26g/cm³
• CAS DataBase Reference: N,N-dihydroxybenzenecarboximidamide(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-dihydroxybenzenecarboximidamide(2086-01-3)
• EPA Substance Registry System: N,N-dihydroxybenzenecarboximidamide(2086-01-3)

Safety Data

• Hazardous Substances Data: 2086-01-3(Hazardous Substances Data)

Upstream product

• 7803-49-8 hydroxylamine 
• 698-16-8 benzohydroximoyl chloride 
• 932-90-1 Benzaldoxime 
• 100-52-7 benzaldehyde 
• 934-16-7 phenylhydroxamoyl chloride 
• 613-92-3 N-hydroxyl-benzamidine 

Downstream Products

• 613-92-3 N-hydroxybenzenecarboximidamide 
• 1605302-52-0 4-hydroxy-3-phenyl-1-oxa-2,4-diazaspiro[4.5]dec-2-ene 
• 16227-05-7 4-hydroxy-5,5-dimethyl-3-phenyl-4,5-dihydro-1,2,4-oxadiazole 
• 1605302-51-9 4-hydroxy-3-phenyl-1,2,4-oxadiazaspiro[4.4]non-2-ene 
• 3354-63-0 α-nitroso-benzaldehyde-oxime 
• 100-47-0 benzonitrile 

Relevant articles and documents

Synthesis and characterization of para-substituted N,N′- dihydroxybenzamidines and their derivatives as model compounds for a class of prodrugs

A synthetic strategy for previously unknown para-substituted N,N′-dihydroxybenzamidines and their O-monosubstituted and O,O′-disubstituted methyl, benzyl, and tetrahydropyranyl derivatives is described. The procedure starts with the corresponding hydroxam

N,N′-dihydroxyamidines: A new prodrug principle to improve the oral bioavailability of amidines

N,N′-Dihydroxybenzamdine represents a model compound for a new prodrug principle to improve the oral bioavailability of drugs containing amidine functions. The activation of the prodrug could be demonstrated in vitro by porcine and human subcellular enzyme fractions, the mitochondrial benzamidoxime reducing system, and porcine hepatocytes. In vivo, the bioavailability of benzamidine after oral application of N,N′- dihydroxybenzamidine was about 91% and exceeded that of benzamidine after oral application of benzamidoxime, being about 74% (Liu, L.; Ling, Y.; Havel, C.; Bashnick, L.; Young, W.; Rai, R.; Vijaykumar, D.; Riggs, J. R.; Ton, T.; Shaghafi, M.; Graupe, D.; Mordenti, J.; Sukbuntherng, J. Species comparison of in vitro and in vivo conversion of five N-hydroxyamidine prodrugs of fVIIA inhibitors to their corresponding active amidines. Presented at the 13th North America ISSX Meeting, Maui, HI, 2005).